IDEXX Labs (IDXX) Cash Flow Statement

Click line-items for a historical chart and %

Net income	169.68M
Depreciation and amortization	57.98M
Loss on disposal of property and equipment
Increase (decrease) in deferred compensation liability
Provision for uncollectible accounts	842K
Provision for (benefit of) deferred income taxes	6.24M
Share-based compensation expense	15.02M
Tax benefit from exercises of stock options and vesting of restricted stock units	-10.23M
Accounts receivable	-16.65M
Inventories	-2.5M
Other assets
Accounts payable	-2.5M
Accrued liabilities
Deferred revenue	3.8M
Net cash provided by operating activities
Purchases of property and equipment	-49.96M
Proceeds from disposition of pharmaceutical product lines
Proceeds from sale of property and equipment
Acquisitions of intangible assets
Net cash used by investing activities
Borrowings on revolving credit facilities, net	-85M
Payment of notes payable
Repurchases of common stock	-91.56M
Proceeds from exercises of stock options and employee stock purchase plans	28.82M
Tax benefit from exercises of stock options and vesting of restricted stock units	10.23M
Net cash used by financing activities
Net effect of changes in exchange rates on cash	4.34M
Net increase in cash and cash equivalents	21.08M
Cash and cash equivalents at beginning of period	128.99M
Cash and cash equivalents at end of period	150.07M

Entities mentioned with IDXX

View All Entities